LIMK1 and prostate cancer: Taken together, these results confirmed that overexpression of miR-17-92a reduced synthesis of proteins involved in activation of RhoGTPase pathway (FGD4) [44], actin cytoskeleton reorganization (LIMK1) [45, 46] and cell cycle regulation (SSH1, cyclin D1) that are often hyper-activated or over-expressed in advanced prostate cancer [47–49].